Visual failure during replacement therapy in primary hypothyroidism with pituitary enlargement.
A 34-year-old woman with longstanding untreated thyroprivic hypothyroidism and pituitary enlargement is reported here in whom visual failure coincided with thyroid hormone replacement. Visual fields were normal after 30 years untreated hypothyroidism, but severe concentric field constriction developed during the first 6 months of therapy and was relieved by hypophysectomy. Plasma TSH and prolactin remained elevated during 10 months replacement therapy, but both were suppressed by preoperative hyperreplacement with T3 and T4. The paradoxical pressure symptoms suggest imbalance between pituitary TSH content and TSH release during treatment with thyroid hormone; a finding previously reported in animal studies. This sequence suggests that patients with known pituitary enlargement secondary to thyroid hypofunction should be observed for pressure symptoms during thyroid hormone treatment.
D000328:Adult; D005260:Female; D006801:Humans; D006965:Hyperplasia; D007037:Hypothyroidism / Q000188:drug therapy*; D010900:Pituitary Diseases / Q000150:complications* / Q000378:metabolism; D011388:Prolactin / Q000097:blood; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism; D013974:Thyroxine / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D014284:Triiodothyronine / Q000097:blood / Q000627:therapeutic use; D014786:Vision Disorders / Q000209:etiology* / Q000601:surgery; D014794:Visual Fields
D014284:Triiodothyronine; D011388:Prolactin; D013972:Thyrotropin; D013974:Thyroxine